Compare LEGN & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGN | RDNT |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.7B |
| IPO Year | 2020 | 1986 |
| Metric | LEGN | RDNT |
|---|---|---|
| Price | $22.53 | $73.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $69.58 | ★ $83.60 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 11-12-2025 | 11-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $909,045,000.00 | ★ $1,969,599,000.00 |
| Revenue This Year | $68.52 | $11.77 |
| Revenue Next Year | $48.63 | $10.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 74.75 | 11.09 |
| 52 Week Low | $21.19 | $45.00 |
| 52 Week High | $45.30 | $85.84 |
| Indicator | LEGN | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 33.52 | 43.38 |
| Support Level | $21.19 | $71.51 |
| Resistance Level | $23.24 | $76.81 |
| Average True Range (ATR) | 1.04 | 3.58 |
| MACD | 0.18 | -0.25 |
| Stochastic Oscillator | 21.26 | 57.38 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.